Carregant...
Miniatura

Tipus de document

Article

Versió

Versió publicada

Data de publicació

Llicència de publicació

cc-by (c) Guercetti, Julian et al., 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/220776

Immuno-μSARS2 Chip: A Peptide-Based Microarray to Assess COVID-19 Prognosis Based on Immunological Fingerprints

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Resum

A multiplexed microarray chip (Immuno-μSARS2) aiming at providing information on the prognosis of the COVID-19 has been developed. The diagnostic technology records information related to the profile of the immunological response of patients infected by the SARS-CoV-2 virus. The diagnostic technology delivers information on the avidity of the sera against 28 different peptide epitopes and 7 proteins printed on a 25 mm2 area of a glass slide. The peptide epitopes (12–15 mer) derived from structural proteins (Spike and Nucleocapsid) have been rationally designed, synthesized, and used to develop Immuno-μSARS2 as a multiplexed and high-throughput fluorescent microarray platform. The analysis of 755 human serum samples (321 from PCR+ patients; 288 from PCR– patients; 115 from prepandemic individuals and classified as hospitalized, admitted to intensive-care unit (ICU), and exitus) from three independent cohorts has shown that the chips perform with a 98% specificity and 91% sensitivity identifying RT-PCR+ patients. Computational analysis utilized to correlate the immunological signatures of the samples analyzed indicate significant prediction rates against exitus conditions with 82% accuracy, ICU admissions with 80% accuracy, and 73% accuracy over hospitalization requirement compared to asymptomatic patients’ fingerprints. The miniaturized microarray chip allows simultaneous determination of 96 samples (24 samples/slide) in 90 min and requires only 10 μL of sera. The diagnostic approach presented for the first time here could have a great value in assisting clinicians in decision-making based on the information provided by the Immuno-μSARS2 regarding progression of the disease and could be easily implemented in diagnostics of other infectious diseases.

Matèries (anglès)

Citació

Citació

GUERCETTI, Julian, ALORDA, Marc, SAPPIA, Luciano, GALVE, Roger, DURAN-CORBERA, Macarena, PULIDO, Daniel, BERARDI, Ginevra, ROYO, Miriam, LACORNA, Alicia, MUÑOZ GUTIÉRREZ, José, PADILLA, Eduardo, CASTAÑEDA, Silvia, SENDRA, Elena, HORCAJADA GALLEGO, Juan pablo, GUTIÉRREZ GÁLVEZ, Agustín, MARCO COLÁS, Santiago, SALVADOR, J. pablo, MARCO, M. pilar. Immuno-μSARS2 Chip: A Peptide-Based Microarray to Assess COVID-19 Prognosis Based on Immunological Fingerprints. _American Chemical Society_. 2025. Vol. 8, núm. 3. [consulta: 30 de gener de 2026]. ISSN: 2575-9108. [Disponible a: https://hdl.handle.net/2445/220776]

Exportar metadades

JSON - METS

Compartir registre